186 related articles for article (PubMed ID: 34581610)
1. Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer.
Giuliani J; Mantoan B; Bonetti A
J Oncol Pharm Pract; 2022 Jan; 28(1):199-202. PubMed ID: 34581610
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Li S; Hu H; Ding D; Zhu Y; Huang J
Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
[TBL] [Abstract][Full Text] [Related]
3. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.
Kopetz S; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Belani A; Zhang X; Tabernero J
ESMO Open; 2022 Jun; 7(3):100477. PubMed ID: 35653981
[TBL] [Abstract][Full Text] [Related]
4. Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation.
Al-Salama ZT
Drugs; 2021 May; 81(7):849-856. PubMed ID: 33914242
[TBL] [Abstract][Full Text] [Related]
5. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated
Tabernero J; Grothey A; Van Cutsem E; Yaeger R; Wasan H; Yoshino T; Desai J; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Elez E; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
J Clin Oncol; 2021 Feb; 39(4):273-284. PubMed ID: 33503393
[TBL] [Abstract][Full Text] [Related]
6. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
Patel KK; Stein S; Lacy J; O'Hara M; Huntington SF
JAMA Netw Open; 2021 Jan; 4(1):e2033441. PubMed ID: 33433598
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.
Trouiller JB; Macabeo B; Poll A; Howard D; Buckland A; Sivignon M; Clay E; Malka D; Samalin E; Toumi M; Laramée P
BMJ Open; 2022 Nov; 12(11):e063700. PubMed ID: 36410812
[TBL] [Abstract][Full Text] [Related]
9. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract][Full Text] [Related]
10. Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study.
Tabernero J; Velez L; Trevino TL; Grothey A; Yaeger R; Van Cutsem E; Wasan H; Desai J; Ciardiello F; Yoshino T; Gollerkeri A; Maharry K; Christy-Bittel J; Kopetz S
ESMO Open; 2021 Dec; 6(6):100328. PubMed ID: 34896698
[TBL] [Abstract][Full Text] [Related]
11. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
[TBL] [Abstract][Full Text] [Related]
12. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR
Elez E; Kopetz S; Tabernero J; Bekaii-Saab T; Taieb J; Yoshino T; Manji G; Fernandez K; Abbattista A; Zhang X; Morris VK
Future Oncol; 2024 Apr; 20(11):653-663. PubMed ID: 37815847
[TBL] [Abstract][Full Text] [Related]
13. TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III
Boku S; Satake H; Ohta T; Mitani S; Kawakami K; Suzuki Y; Matsumoto T; Terazawa T; Yamazaki E; Hasegawa H; Ikoma T; Uemura M; Yamaguchi T; Naito A; Ishizuka Y; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Tsujinaka T; Kato T; Satoh T; Kagawa Y
Future Oncol; 2022 Dec; 18(38):4153-4160. PubMed ID: 36475784
[TBL] [Abstract][Full Text] [Related]
14. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
Van Cutsem E; Huijberts S; Grothey A; Yaeger R; Cuyle PJ; Elez E; Fakih M; Montagut C; Peeters M; Yoshino T; Wasan H; Desai J; Ciardiello F; Gollerkeri A; Christy-Bittel J; Maharry K; Sandor V; Schellens JHM; Kopetz S; Tabernero J
J Clin Oncol; 2019 Jun; 37(17):1460-1469. PubMed ID: 30892987
[TBL] [Abstract][Full Text] [Related]
15. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
[TBL] [Abstract][Full Text] [Related]
16.
Imai T; Shoji H; Hirano H; Matsuguma K; Awatsu T; Hirose T; Okita N; Takashima A; Kato K
CNS Oncol; 2024 Jun; 13(1):2347824. PubMed ID: 38869444
[TBL] [Abstract][Full Text] [Related]
17. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
Trullas A; Delgado J; Koenig J; Fuerstenau U; Dedorath J; Hausmann S; Stock T; Enzmann H; Pignatti F
ESMO Open; 2021 Feb; 6(1):100031. PubMed ID: 33422765
[TBL] [Abstract][Full Text] [Related]
18. Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF
Ji J; Wang C; Fakih M
Clin Colorectal Cancer; 2022 Sep; 21(3):267-271. PubMed ID: 35039233
[No Abstract] [Full Text] [Related]
19. Retrospective Analysis of Treatment Pathways in Patients With BRAF
Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
[TBL] [Abstract][Full Text] [Related]
20. The BEETS (JACCRO CC-18) trial: an observational and translational study of
Inagaki C; Matoba R; Yuki S; Shiozawa M; Tsuji A; Inoue E; Muro K; Ichikawa W; Fujii M; Sunakawa Y
Future Oncol; 2023 Jun; 19(17):1165-1174. PubMed ID: 37458152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
